Trametinib Kinase Inhibitor yana Nufin BRAF V600 Maye Gurbi-Maganin Ciwon daji

Farashin: USD 8-15/g

Sunan samfur Trametinib
CAS No. 871700-17-3
MF Saukewa: C26H23FIN5O4
MW 615.402623
Yawan yawa 1.743
Wurin narkewa 293-303 ° C

Tuntube mu

samfurin bayani

Cikakken Bayani

Trametinib shine mai hanawa kinase mai ƙarfi da zaɓin da aka yi amfani da shi da farko don maganin melanoma wanda ba a iya ganowa ko metastatic tare da maye gurbin BRAF V600, da kuma takamaiman nau'ikan ci gaba ko ƙaƙƙarfan ciwon huhu mara ƙarami. Wannan labarin yana bincika tsarin aiki, alamun asibiti, da fa'idodin trametinib a cikin maganin maye gurbi na BRAF V600-tabbataccen ciwon daji.

I. Fahimtar Trametinib:

A. Mai hanawa na baka, mai ƙarfi, da zaɓin kinase

B. Ya kasance na ajin masu hana MEK

C. Yana toshe ayyukan kinase na MEK1 da MEK2

D. Yana hana alamar ERK1 da ERK2 na ƙasa

II. Alamun asibiti:

A. Melanoma wanda ba a iya ganowa ko metastatic melanoma mai ɗauke da maye gurbin BRAF V600:

Magungunan haɗin gwiwa tare da dabrafenib mesylate

B. Adjuvant far bayan tiyata don maye gurbin BRAF V600 mai kyau melanoma:

Magani na adjuvant tare da dabrafenib mesylate bayan cikakken resection

III. Matsayin Ciwon Kankara Na Huhu Mara Karami:

A. Ciwon daji na huhu mara ƙanƙanta a matsayin babban abin da ke haifar da cututtuka da mace-mace

Halin maye gurbi na BRAF da yawaitar maye gurbi na BRAF V600E

C. Tasirin hanawa na Trametinib akan BRAF V600 maye gurbi-tabbataccen ƙwayoyin melanoma

IV. Tsarin Aiki:

A. Reversible hanawa na mitogen- kunna extracellular siginar-regulated kinase (MEK) 1 da MEK2

B. Tasiri kan hanyar MAPK da furotin MEK

C. Hana yaduwar kwayar halitta da hanyar ERK na ƙasa

V. Maganin Adjuvant Bayan Yin aiki:

A. Fa'idodin maganin haɗuwa da aka yi niyya tare da Dabrafenib da Trametinib

B. Dogon lokaci, fa'idodin rayuwa marar ɗorewa (RFS) a cikin babban haɗari mataki III BRAF maye gurbi-masu ciwon melanoma

Trametinib, mai hana kinase da aka yi niyya, yana nuna tasiri mai mahimmanci a cikin jiyya na BRAF V600 maye gurbi-tabbataccen ciwon daji, musamman mara lahani ko melanoma na metastatic da takamaiman nau'ikan cutar kansar huhu mara kanana. Tsarin aikinsa, yana hana MEK1 da MEK2 kinase ayyukan, yana haifar da hanawa ta hanyar ERK da ke ƙasa da kuma hana yaduwar kwayar halitta. Trametinib, a haɗe tare da dabrafenib mesylate, yana ba da fa'idodin warkewa a cikin ci-gaba da saitunan adjuvant ga marasa lafiya na BRAF V600 maye gurbi.
Tuntube mu don shawarwarin magani da bayanin farashin farashi don haɓaka kulawar haƙuri.